WO2019088208A1 - Modèle de stéatohépatite non alcoolique humaine - Google Patents

Modèle de stéatohépatite non alcoolique humaine Download PDF

Info

Publication number
WO2019088208A1
WO2019088208A1 PCT/JP2018/040601 JP2018040601W WO2019088208A1 WO 2019088208 A1 WO2019088208 A1 WO 2019088208A1 JP 2018040601 W JP2018040601 W JP 2018040601W WO 2019088208 A1 WO2019088208 A1 WO 2019088208A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
hepatocytes
animal
chimeric
adjusted feed
Prior art date
Application number
PCT/JP2018/040601
Other languages
English (en)
Japanese (ja)
Inventor
豪 菅原
慧士 喜早
石田　雄二
知世 向谷
小原　道法
Original Assignee
株式会社フェニックスバイオ
公益財団法人東京都医学総合研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社フェニックスバイオ, 公益財団法人東京都医学総合研究所 filed Critical 株式会社フェニックスバイオ
Priority to JP2019550478A priority Critical patent/JP7233039B2/ja
Publication of WO2019088208A1 publication Critical patent/WO2019088208A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Definitions

  • the present invention provides a human non-alcoholic steatohepatitis model obtained by subjecting rodents to a specific treatment, and a method of using a rodent animal subjected to a specific treatment as a human non-alcoholic steatohepatitis model
  • the present invention relates to a method for producing this model, and a method for screening a preventive, ameliorating or therapeutic agent for human non-alcoholic steatohepatitis using this model.
  • liver disease examples include hepatitis virus, alcohol, autoimmunity, primary biliary cholangitis, etc., obesity, diabetes, hypertriglyceridemia, excessive nutrition intake by long-term parenteral nutrition, endocrine disorder, low beta
  • lifestyle habits and lifestyle-related diseases such as lipoproteinemia, starvation and re-replenishment syndromes.
  • non-alcoholic fatty liver disease NAFLD includes simple fatty liver where fats are deposited in hepatocytes, and non-alcoholic steatohepatitis (NASH) in which inflammation occurs and fibrosis progresses with hepatic steatosis.
  • NASH non-alcoholic steatohepatitis
  • NASH Unlike simple fatty liver, NASH progresses to liver cirrhosis and liver cancer, so elucidation of the progress mechanism from simple fatty liver to NASH and accurate discrimination between the two are particularly serious issues.
  • Non-patent Document 1 rats reared on choline and methionine deficient feed are known as animal models of NASH.
  • the decrease in muscle mass causes weight loss, making it difficult to use for continuous observation of NASH symptoms and drug efficacy evaluation.
  • NASH can be induced by rearing rats with a choline deficient methionine-containing feed.
  • the effects of species differences are strong, and even when this feed is given to mice, no fibrosis characteristic of NASH is observed (Non-patent Document 1).
  • livers of these model animals are non-human animal livers, they are not animal models that completely reproduce human NASH, and their metabolic activities in the liver are also non-human animal types. Therefore, it is difficult to say that it is a model suitable for evaluating the efficacy of human NASH.
  • Patent Document 1 prepares a primary chimeric non-human animal by implanting human hepatocytes into a liver disorder immunodeficient non-human animal to produce a primary chimeric non-human animal, and separates human hepatic cells from the liver of this primary chimeric non-human animal by collagenase perfusion method
  • chimeric liver nonhuman animals obtained by transplantation into a new liver injury immunodeficient nonhuman animal macroscopic lipid deposition and swelling of human hepatocytes are observed in human hepatocytes, and it is preferable to surround human hepatocytes. It is disclosed that inflammatory cells centering on neutrophils are accumulated, and a fibrotic image is also observed, exhibiting symptoms of NASH.
  • the passage-transplanted chimeric non-human animal taught by Patent Document 1 is expected to be able to be used as an animal model reproducing human NASH because most of its liver is replaced with human hepatocytes.
  • the NASH symptom of the chimeric non-human animal taught by Patent Document 1 has low reproducibility, and it is difficult to put into practical use as an animal model to be widely used for screening of NASH therapeutic agents and the like.
  • this method in order to produce NASH by transplanting human hepatocytes, there is also a disadvantage that it is not possible to set a non-NASH group to which human hepatocytes are transplanted, that is, a control group.
  • the present invention provides a rodent animal model that stably exhibits human NASH symptoms, a method for producing this model, a method for using rodents stably presenting human NASH symptoms as a human NASH model, and such a rat.
  • An object of the present invention is to provide a method for screening a human NASH therapeutic agent using rodents.
  • the present inventors repeated studies to solve the above-mentioned problems, and chimera rodents in which a part or all of the hepatocytes were replaced with human hepatocytes were used with 0.01% by weight of choline or a salt thereof.
  • a compounded feed in which the content of methionine is adjusted to 0.5% by weight or less and the fat content is adjusted to 25 kcal% or more, macroscopic fat deposition in the liver, as shown in the item of the example, We found that there are characteristic lesions in NASH such as fibrosis, infiltration of inflammatory cells, ballooning of hepatocytes (balloon-like swelling), and Mallory body.
  • the present inventor found that feeding human hepatocyte chimeric rodent animals with the above-described adjusted diet does not change the alanine transaminase (ALT) concentration of rodent animals and increases the human ALT1 concentration.
  • ALT alanine transaminase
  • the above-mentioned adjusted diet can induce liver damage specifically to human hepatocytes without inducing damage to the hepatocytes of recipient animals remaining in human hepatocyte chimeric rodents. Also in this respect, it is understood that the above-mentioned adjusted feed can induce symptoms characteristic of human NASH.
  • NASH symptoms can be reproducibly introduced by breeding human hepatocyte chimera rodents with the above-described adjusted diet. Therefore, it was found that human hepatocyte chimera rodents reared with the above-described adjusted feed can be put to practical use as animal models for research on the pathogenesis of NASH and drug efficacy screening.
  • human hepatocytes engrafted in the liver function by interaction with rodent cells in other tissues or organs and hepatocytes in rodents remaining in the liver. Do. For this reason, there is a possibility that mouse hepatocytes and human hepatocytes have different sensitivities to various disorders, and it is often difficult to specifically damage human hepatocytes.
  • inflammation and fibrosis prepared by administering carbon tetrachloride (CCl 4 ) to normal mice are generally used as a hepatitis or cirrhosis model, but human liver It is difficult to obtain a hepatitis or cirrhosis model due to human hepatocyte injury, since administration of CCl 4 to cell chimeric mice causes much more damage and necrosis to mouse hepatocytes than human hepatocytes. Under such circumstances, it was possible to specifically damage human hepatocytes and strongly express human NASH characteristic lesions by giving human hepatocyte chimeric rodents the above-mentioned adjusted diet. It is surprising.
  • Non-Patent Document 1 there are species differences among rodents in induction of lesions by adjusted diets. Also in this respect, it is surprising that administration of the adjusted diet was able to induce NASH in the livers of human hepatocytes-replaced rodents.
  • a chimeric rodent animal in which part or all of hepatocytes are replaced with human hepatocytes is fed with a modified feed having one or more of the following characteristics (a), (b) and (c):
  • Human non-alcoholic steatohepatitis model including animals obtained by (a) The content of choline or its salt is 0.01% by weight or less based on the total amount of the adjusted feed (b) The content of methionine is 0.5% by weight or less based on the total weight of the adjusted feed (c) Fat content is 25 kcal% or more based on the total heat of protein, carbohydrate and fat contained in the adjusted feed
  • Chimera rodents are primary chimera rodents or passaged transplants The human non-alcoholic steatohepatitis model according to [1], which is a chimeric rodent.
  • a chimeric rodent animal in which part or all of hepatocytes are replaced with human hepatocytes is fed with a modified feed having one or more of the following characteristics (a), (b) and (c):
  • a method of producing a human non-alcoholic steatohepatitis model comprising the steps of: (a) The content of choline or its salt is 0.01% by weight or less based on the total amount of the adjusted feed (b) The content of methionine is 0.5% by weight or less based on the total weight of the adjusted feed (c) Fat content is at least 25 kcal% relative to the total heat of protein, carbohydrate and fat contained in the adjusted feed [8]
  • Chimeric rodents are primary chimera rodents or passaged transplants The method according to [7], which is a chimeric rodent.
  • a chimeric rodent animal in which part or all of hepatocytes are replaced by human hepatocytes is fed with a modified feed having one or more of the following characteristics (a), (b) and (c): Comparing the degree of symptoms of non-alcoholic steatohepatitis before and after administration with the step of administering the test substance to an animal obtained by the method comprising the step, or comparing the chimeric rodent and the test substance with the test substance administered And c. Comparing the degree of symptoms of nonalcoholic steatohepatitis with a chimeric rodent which has not been administered.
  • a chimeric rodent animal in which part or all of hepatocytes are replaced with human hepatocytes is fed with a modified feed having one or more of the following characteristics (a), (b) and (c): Use of the animal obtained thereby as a human non-alcoholic steatohepatitis model.
  • the human NASH animal model of the present invention is different from the conventional rodent NASH model because all or part of the liver is replaced with human hepatocytes, and exhibits various symptoms characteristic of human NASH. It is a model that accurately reproduces NASH.
  • the human NASH animal model of the present invention also demonstrates that the transplanted human hepatocytes are specifically damaged, which also exhibits the characteristic lesion of human NASH.
  • the NASH model of a rodent animal having conventional human hepatocytes showed no reproducibility in NASH symptoms, the NASH symptoms in the human NASH animal model of the present invention are reproducible.
  • human hepatocyte chimera rodents fed a normal diet have simple fatty liver but do not progress to NASH, so the human NASH animal model of the present invention is a human hepatocyte with this simple fatty liver.
  • Chimeric rodents can be used as control animals. The present inventors have found that the primary chimeric rodent animal exhibits symptoms of simple fatty liver, and it is reported in Patent Document 1. However, the passaged chimeric chimeric rodent has simple fatty liver.
  • the human NASH animal model of the present invention reproducibly forms a human NASH pathological condition, and in that it can be compared with a control animal, the NASH model using human hepatocyte chimeric rodent animal reported in Patent Document 1 It can be said that it is a better model. From these facts, the model of the present invention can be suitably used as a pathological model animal that accurately reflects the pathological state of human NASH, for research on the onset mechanism of NASH, screening of a preventive or therapeutic agent thereof, and the like.
  • FIG. 4 is a hematoxylin-eosin stained image (magnification: 400 ⁇ ) of a liver section after feeding a passage-transplanted chimeric mouse (human hepatocyte Lot No. BD195) with a superhigh fat choline deficient methionine reduced diet or a normal diet.
  • FIG. 6 is a hematoxylin-eosin stained image (magnification: 400 ⁇ ) of a liver section after feeding a passage-transplanted chimeric mouse (human hepatocyte Lot No. IVTJFC) with a superhigh fat choline deficient methionine reduced diet or a normal diet.
  • Sirius red stained image of the liver section after rearing a passage transplant chimera mouse (human hepatocyte Lot No. BD195) by superhigh fat choline deficiency methionine reduction diet or a regular diet.
  • Sirius red stained image of a liver section after rearing a passage transplant chimera mouse (human hepatocyte Lot No. IVTJFC) by superhigh fat choline deficiency methionine reduction diet or a regular diet.
  • the ratio of the fibrotic area calculated from the Sirius red staining image of the liver section after rearing the passage-transplanted chimeric mouse (human hepatocyte Lot No. BD 195) with super high fat choline deficient methionine reduced diet or normal diet is shown.
  • IVTJFC on a superhigh fat choline deficient methionine reduced diet or a normal diet. It is a Sirius red stained image of a liver section after rearing a primary chimera mouse (human hepatocyte Lot No. IVTJFC) with a superhigh fat choline deficient methionine reduced diet or a normal diet. It is an anti-F4 / 80 antibody immunostaining image of the liver section after rearing a primary chimera mouse (human hepatocyte Lot No. IVTJFC) on superhigh fat choline deficient methionine reducing diet or a normal diet.
  • the method for producing a human non-alcoholic steatohepatitis (NASH) model of the present invention is a chimera antibody in which part or all of the hepatocytes are replaced with human hepatocytes.
  • a group consisting of (a) 0.01% by weight or less of choline or a salt thereof, 0.5% by weight or less of a methionine, and (c) a fat content of 25 kcal% or more It is a method including the step of rearing on a conditioned feed having at least one characteristic selected.
  • the chimeric rodent animal in which part or all of the human hepatocytes are replaced with human hepatocytes can be prepared by transplanting human hepatocytes into an immunodeficient hepatopathic rodent ( Primary chimera animal).
  • an immunodeficient hepatopathic rodent Primary chimera animal
  • passage-transplanted chimeric rodents transplant human hepatocytes grown in the body of primary chimeric rodents into the above-mentioned immunodeficient hepatopathic rodents and allografts with immunocompromised hepatopathic rodents. It can be obtained by Transplantation of human hepatocytes grown in chimeric rodents can be performed one or more times.
  • Rodents include mice, rats such as rats, guinea pigs, squirrels, hamsters and the like, but mice commonly used as experimental animals and rats such as rats are easy to use. Either male or female may be used, but male is preferred.
  • Rodent immunodeficiency Hepatic disorder Rodent animals are immunodeficiency that does not show rejection of cells from xenogeneic animals, and the native liver cells of rodents are impaired. It is an animal that receives it. Since the native cells of the animal are damaged, if liver cells are transplanted, the liver function is maintained by the transplanted human hepatocytes, and the animal accurately reflects the intra-individual function of human hepatocytes. become. In addition, human hepatocytes to be transplanted are easily proliferated.
  • the immunodeficient liver disorder animal can be produced by subjecting the same individual to a liver injury induction treatment and an immunodeficiency induction treatment.
  • Treatment for inducing liver injury includes administration of liver injury inducers such as carbon tetrachloride, yellow phosphorus, D-galactosamine, 2-acetylaminofluorene, pyrrolidine alkaloid, irradiation, surgical partial resection of liver, etc. It can be mentioned.
  • the immunodeficiency inducing treatment includes administration of an immunosuppressant and thymectomy.
  • an immunodeficient liver disorder animal can also be prepared by subjecting a genetically immunodeficient animal to a liver injury inducing treatment.
  • genetic immunodeficiency animals animals with severe combined immunodeficiency (SCID: severe combined immunodeficiency) showing T cell line dysfunction, animals with loss of T cell function due to hereditary thymus defect, RAG2 gene known Examples include animals that have been knocked out by gene targeting (Science, 244: 1288 1292, 1989) or genome editing techniques.
  • SCID mice Specifically, SCID mice, RAG2 knockout mice, IL2Rgc / Rag2 knockout mice, NOD mice, NOG mice, nude mice, nude rats, immunodeficient rats obtained by implanting SCID mouse bone marrow into X-irradiated nude rats (Japanese Patent Application Laid-Open No. 2007-228962, Transplantation. 60 (7): 740-7, 1995) and the like.
  • an immunodeficient liver disorder animal can also be prepared by subjecting a genetically liver disordered animal to an immunodeficiency inducing treatment.
  • a genetically liver-injured animal a known transgenic method (Proc. Natl. Acad.) Is used using a liver injury-inducing protein gene linked under the control of a liver cell-specifically expressed protein enhancer and / or promoter. Sci. USA 77; 7380-7384 (1980)).
  • the liver injury-inducing protein is expressed specifically in the liver, and thus has liver injury. Proteins specifically expressed in the liver include serum albumin, cholinesterase, Hageman factor and the like.
  • Liver injury-inducing proteins include urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and the like.
  • uPA urokinase plasminogen activator
  • tPA tissue plasminogen activator
  • an animal having genetic liver disorder can be obtained by knocking out a gene responsible for liver function such as the fumaryl acetoacetate hydrolase gene.
  • liver damage can be caused by administering ganciclovir to a mouse into which a thymidine kinase gene has been introduced under the albumin enhancer promoter.
  • an immunodeficient liver disorder animal can also be produced by crossing a genetically immunodeficient animal with a genetic liver disorder animal of the same species.
  • a genetically immunocompromised liver disorder animal an animal whose liver injury gene and immunodeficiency gene are homozygous or heterozygous can be used, respectively.
  • Human hepatocytes used for transplantation can be isolated from human liver tissue by a conventional method such as collagenase perfusion. For example, by using human hepatocytes of children under 14 years of age, high rates of substitution by human hepatocytes are achieved.
  • proliferating hepatocytes having active proliferative ability in vivo are used, human hepatocyte population that can rapidly proliferate in the recipient rodent body and can exert normal liver function can be obtained in a short time. It can be formed. Examples of such proliferating human hepatocytes include human small hepatocytes invented by the present inventors (JP-A-8-112092 etc.) and the like.
  • human hepatic cells obtained from hepatic progenitor cells such as Clip cells, and pluripotent stem cells such as iPS cells and ES cells can also be used.
  • Human hepatocytes can be transplanted into the liver via the spleen of an immunocompromised liver injury animal. It can also be transplanted directly from the portal vein.
  • the number of human hepatocytes to be transplanted can be about 1 to 2 million.
  • the sex of the immunodeficient liver injury animal is not particularly limited.
  • the age of the immunodeficient liver-damaged animal at the time of transplantation is not particularly limited, but when human hepatocytes are transplanted when the mouse is low age, human hepatocytes can be more actively proliferated as the mouse grows. From the point of view, it is preferable to use an animal of about 6 weeks of age immediately after birth.
  • the animal after transplantation may be bred by a conventional method. For example, by rearing for about 3 to 30 weeks after transplantation, a primary chimeric animal in which part or all of the hepatocytes are replaced with human hepatocytes can be obtained.
  • Human hepatocytes grown in a chimeric animal can be recovered, for example, by collagenase treatment of a liver tissue of the chimeric animal.
  • the cytotoxicity of collagenase is higher for rodent hepatocytes than for human hepatocytes, so by adjusting the collagenase treatment time, the hepatocytes of chimeric animals are damaged, and almost only human hepatocytes are isolated. can do.
  • non-hepatic parenchymal cells and hepatocytes of recipient animals are also contained in small amounts.
  • the recovered hepatocytes may be used as they are for transplantation, but the purity of human hepatocytes can also be increased using a monoclonal antibody that specifically recognizes human hepatocytes or recipient animal hepatocytes.
  • Transplantation and expansion of human hepatocytes isolated from primary chimeric animals to the liver of rodents are the same as in the production of primary chimeric animals.
  • both primary chimeric rodents and passage-transplanted chimeric rodents can be used.
  • Passage-transplanted chimeric rodents may be transplanted one time or may be transplanted two or more times.
  • chimeric rodents transplanted two to four times can be used.
  • human NASH symptoms can be sufficiently introduced by rearing on adjusted diets.
  • the adjusted feed used in the present invention is one in which the amount of choline or its salt is reduced, the amount of choline or its salt added is 0.01 relative to the total amount of the adjusted feed (that is, the final concentration is 0.01). % By weight or less is preferable, 0.001% by weight or less is more preferable, and it is most preferable that no choline or a salt thereof is blended or substantially not blended. Thereby, NASH symptoms can be sufficiently induced. In addition, there is no hindrance to growth even if it does not mix choline or its salt.
  • the compounding amount of choline or its salt mentioned here is the addition amount of choline or its salt to feed.
  • Choline has the following formula (1) It is a quaternary ammonium cation shown by Choline salts include, but are not limited to, chlorides, hydroxides, phosphates, monohydrogen phosphates, dihydrogen phosphates, carbonates, hydrogen carbonates, inorganic salts such as sulfates; tartaric acid Typical examples are salts, hydrogen tartrate (bitartrate), citrate, acetate, oxalate, lactate, malate, malate, fumarate, malonate, organic salts such as succinate Organic salts can be mentioned.
  • choline is usually present as a salt.
  • the methionine content is preferably 0.5% by weight or less, more preferably 0.2% by weight or less, based on the total amount of the adjusted sample (that is, the final concentration is). Is more preferably 0.1% by weight or less.
  • the methionine content can be 0.03% by weight or more, 0.05% by weight or more, or 0.1% by weight or more. Within this range, it is possible to put it into practical use as an experimental animal by inducing a NASH symptom and suppressing a decrease in body weight due to a decrease in muscle mass.
  • the methionine content here is the amount of methionine added to the feed.
  • the raw material in the feed for rearing rodents may naturally contain a trace amount of methionine, its content is usually negligible. Also, methionine constituting the peptide is not included in the methionine blending amount referred to herein.
  • the fat content is 25 kcal% or more based on the total heat quantity (100 kcal%) of protein, carbohydrate and fat in the feed It is preferable to set it as 40 kcal% or more, especially 50 kcal% or more, and more preferably 60 kcal% or more. Thereby, NASH symptoms can be sufficiently induced.
  • the fat content is 120 kcal% or less, particularly 90 kcal% or less, 70 kcal% or less, 60 kcal% or less based on the total heat quantity (100 kcal%) of protein, carbohydrate and fat in feed. It can be done. Within this range, it can be practically used as an experimental animal while inducing NASH symptoms.
  • the fat content is 10% by weight or more, particularly 20% by weight or more, and particularly 30% by weight, with respect to the total amount of the adjusted feed.
  • the content is preferably 35% by weight or more.
  • the fat content can be 70% by weight or less, in particular 60% by weight or less, and in particular 50% by weight or less, based on the total amount of the adjusted feed. Within this range, it can be practically used as an experimental animal while inducing NASH symptoms.
  • the "fat" in the adjusted feed includes any of vegetable fats, animal fats, and mineral fats.
  • vegetable oils include, but are not limited to, corn oil, soybean oil, sesame oil, rapeseed oil, rice oil, soy sauce, soy sauce, safflower oil, coconut oil, cotton seed oil, sunflower oil, sesame oil, sesame oil, linseed oil, olive oil, peanut oil Almond oil, avocado oil, hazelnut oil, walnut oil, grape seed oil, cocoa butter, peanut butter and the like.
  • Animal fats and oils include soy sauce, soy sauce, liver oil, horse oil, pork fat, beef tallow, horse fat, milk fat, and their hardened fats and oils.
  • the adjusted feed used in the present invention has a content of (a) choline or a salt thereof of 0.01% by weight or less, a content of (b) methionine of 0.5% by weight or less, and (c) a fat content of 25 kcal% or more It has only to have one or two or more characteristics. Specifically, (a), (b), (c), (a) and (b), (a) and (c), (b) and (c), and (a) and (b) Any of (c) may be used. Among them, the combination of (a), (b) and (c) is preferable.
  • the adjusted feed used in the present invention contains nutrients such as proteins, carbohydrates, minerals, vitamins and the like which are usually contained in animal feed as long as the above (a), (b) and / or (c) are satisfied. Can.
  • the chimeric rodents are administered the adjusted diet at a human hepatocyte substitution rate of at least 30%, particularly at least 50%, and more preferably at least 70% for both primary chimera animals and passaged transplant chimera animals. It is preferable to start doing. In addition, it may be possible to start administration of the adjusted diet in a state where the human hepatocyte replacement rate has reached 80% or more, or 90% or more, or all hepatocytes of rodents have been replaced with human hepatocytes. .
  • Human hepatocyte replacement rate can be obtained, for example, by preparing a liver section of a chimeric animal and staining (for example, hematoxylin-eosin staining) to measure the area ratio of human hepatocytes, or for an antibody specific for human hepatocytes (for example, Immunostaining can be carried out using cytokeratin 8/18 antibody or STEM121 antibody) to determine the human hepatocyte area ratio (human cytokeratin 8/18 or STEM121 positive area ratio).
  • staining for example, hematoxylin-eosin stain staining
  • Immunostaining can be carried out using cytokeratin 8/18 antibody or STEM121 antibody
  • cytokeratin 8/18 antibody or STEM121 antibody an antibody specific for human hepatocytes
  • the human hepatocyte replacement rate of the outer right lobe slice is highly correlated with the average value of the human hepatocyte replacement rate of all 7 lobe sections, the human hepatocyte replacement rate can also be determined using the outer right lobe slice .
  • the human hepatocyte replacement rate can also be estimated by measuring the concentration of human albumin in the blood of a chimeric animal and fitting it to a previously prepared calibration curve.
  • the adjusted feed When rearing chimeric rodents with a controlled feed, the adjusted feed may be freely fed or forcibly fed.
  • the administration period of the adjusted feed can be 1 week or more, 2 weeks or more, 3 weeks or more, or 4 weeks or more. In addition, it can be 40 weeks or less, 30 weeks or less, 20 weeks or less, or 10 weeks or less. Within this range, NASH symptoms can be sufficiently induced.
  • Non-alcoholic steatohepatitis As described above, human hepatocyte chimeric rodent animals exhibiting human NASH symptoms are obtained, and this animal can be used as a human NASH model (human NASH rodent animal model).
  • Human NASH is one of fat-accumulating liver diseases other than human alcoholic liver disease (non-alcoholic fatty liver disease (NAFLD)), but at least lipid droplet deposition, inflammatory cell infiltration, and fibrosis in the liver. Refers to a disease that exhibits the symptoms of
  • the area ratio of fat droplets observed by staining a liver section is 5% or more, 33% Is more preferably more than 66%.
  • the NAFLD activity score (NAS score) (Hepatology. 2005 Jun; 41 (6): 1313-21) specified by the Nonalcoholic Steatohepatitis Clinical Research Network is “1” when the area ratio of fat droplets is 5% or more and 33% or less. It is “2” when it is more than 33% and not more than 66%, and "3" when it is more than 66%.
  • Inflammatory cell infiltration in the liver may be observed as little as possible, but when a liver section is stained (eg, hematoxylin and eosin staining, Masson's trichrome staining), an inflammatory lesion per ⁇ 200 magnification field in the liver leaflet It is preferable that 1 or more be recognized, It is more preferable to be recognized 2 or more, It is more preferable to be recognized 4 or more. In the above NAS score, “1” when there are 1 or more and less than 2 inflammatory lesions per ⁇ 200 magnification field of liver lobule, “2” when 2 or more and 4 or less, “3” when more than 4 is there.
  • liver sections are stained (eg, Sirius red stain, Masson trichrome stain), it is observed around the sinusoid and at the center of the liver lobule, or around the portal vein.
  • NAS score Fibrosis stage "1" and even more preferably observed both around the sinusoid and around the portal vein (NAS score Fibrosis stage "2"), that crosslinkable fibrosis is observed It is even more preferable (NAS score Fibrosis stage "3"), and even more preferable that cirrhosis is observed (NAS score Fibrosis stage "4").
  • iron deposition and hepatocyte apoptosis may also be observed in the liver of chimeric rodents exhibiting NASH symptoms obtained by the above method.
  • Iron deposition can be confirmed, for example, by iron staining of liver sections or hematoxylin and eosin staining.
  • Apoptosis of hepatocytes is confirmed as apoptotic bodies, for example, in hematoxylin and eosin staining.
  • DNA fragments generated by apoptosis can also be confirmed by detection by TUNEL (TdT-mediated dUTP end labeling) method or immunostaining of activated Caspase 3.
  • oxidative stress is considered to be one of the causes of progression of symptoms from nonalcoholic fatty liver disease (NAFLD) to NASH.
  • CYP2E1 and 4-hydroxy-2-nonenal (4-HNE) are known as proteins that cause oxidative stress.
  • CYP2E1 is an enzyme that generates free radicals
  • 4-HNE is a lipid peroxidase.
  • expression or enhanced expression of proteins that cause oxidative stress such as CYP2E1 and 4-HNE can be observed.
  • the expression of CYP2E1 and 4-HNE can be confirmed by immunostaining of liver sections using human CYP2E1 and human 4-HNE antibodies, respectively.
  • hepatocytes and Mallory body characteristic lesions can be observed in human NASH such as Ballooning (balloon-like swelling) of hepatocytes and Mallory body.
  • the ballooning of the hepatocytes and the mallory body can be confirmed by staining the liver section (for example, hematoxylin and eosin staining, azanmaloli staining, masson trichrome staining).
  • the NAS score is "1" when there are a small number of ballooning degeneration of hepatocytes in the liver and "2" when there are many.
  • ALT human alanine transaminase
  • LDH lactate dehydrogenase
  • NADH nicotinamide adenine dinucleotide reduced form
  • NAD ⁇ -nicotinamide adenine dinucleotide oxidized form
  • Measurement of the ALT activity value can not distinguish between ALT derived from mouse hepatocytes and ALT derived from human hepatocytes, but in addition to the measurement of ALT activity values, if human ALT1 concentration is measured by ELISA etc., it occupies in ALT The ratio of ALT derived from human hepatocytes can be grasped.
  • the method for screening agent for preventing, treating or ameliorating human NASH of the present invention is a test substance in the human NASH rodent animal model of the present invention described above And comparing the degree of NASH symptoms before and after administration of the test substance, or comparing the degree of NASH symptoms between a group to which the test substance is administered and a non-administration group.
  • the comparison of the degree of NASH symptoms before and after administration of the test substance may be performed for any of the above-mentioned symptoms observed in human NASH. That is, in the liver, deposition of lipid droplets, inflammatory cell infiltration, fibrosis, iron deposition, hepatocyte apoptosis, expression of proteins that cause oxidative stress, hepatocytes ballooning, malory body, ALT activity It is also good. Above all, it is preferable to perform deposition of lipid droplets, inflammatory cell infiltration, and / or fibrosis.
  • test substance can be determined to be effective for treatment or amelioration of human NASH. If any NASH symptom is significantly alleviated or ameliorated, the test substance can be determined to be effective for treatment or improvement of human NASH, but 1.3 times or more, 1.5 times or more, or 2 times or more Can be used as an indicator. In addition, since an agent effective for treating or ameliorating a disease is generally also effective for preventing the disease, such a test agent can be determined to be effective for preventing human NASH.
  • the test substance is not particularly limited, and includes low molecular weight compounds, amino acids, nucleic acids, lipids, saccharides, extracts of natural products and the like.
  • the administration route of the test substance is not particularly limited, and oral administration, intraperitoneal administration, intravenous administration, intraarterial administration, subcutaneous administration, intramuscular administration, transdermal administration and the like can be mentioned.
  • the dose of the test substance and the administration schedule such as the number of times of administration can be determined for each test substance so that the presence or absence of the effect can be determined.
  • the degree of NASH symptoms can be confirmed and compared with the degree of NASH symptoms in the non-administration group. Alternatively, the degree of NASH symptoms can be compared before and after administration of the test substance.
  • uPA-Tg mice (hemizygote, +/-) were prepared by the method described in Examples 1 and 2 of JP-A-2013-230093.
  • the uPA gene was extracted from mouse liver by AGPC method (acid-guanidinium-isothiocyanate-phenol-chloroform) and was dissolved in RNase-free water.
  • Sequence of uPA gene registered in the published database using the total RNA obtained above uPA gene specific primer (antisense sequence from 1341 bases to 1360 bases in length prepared from Accession No. NM008873) and Reverse transcription with LongRange Reverse Transcriptase (manufactured by Qiagen) is carried out at 25 ° C. for 10 minutes, then at 42 ° C.
  • the enzyme used was Phusion DNA polymerase (Fynnzymes), and PCR primers (sense sequences of bases 39 to 61) were prepared from the uPA gene sequence (Accession number: NM008873).
  • the fragment to be amplified has nucleotides 39-13 in the PCR reaction
  • the obtained DNA fragment was introduced into an expression plasmid having a mouse albumin promoter / enhancer described later to construct “malb uPAInt2”, which is downstream of the mouse albumin enhancer / promoter.
  • the second exon of rabbit ⁇ globin, the intron, the third exon, the ORF part of mouse uPA, and the polyA signal in the third exon of rabbit ⁇ globin are combined.
  • the plasmid "malb uPAInt2" was introduced into ES cells obtained from 129SvEv mice by electroporation, and then selective culture was performed with G418.
  • the obtained G418 resistant colonies were assayed for ES cells into which a gene had been introduced by PCR as follows.
  • Dulbecco's modified Eagle's medium (DMEM) (Gibco / BRL 11965-084) culture solution contains 15% fetal bovine serum (Hyclone SH30071) and 2 mM L-glutamine (Gibco) / BRL 25030-081), final concentration 100 ⁇ M each non-essential amino acid (Gibco / BRL 11140-050), final concentration 10 mM HEPES (Gibco / BRL 15630-080), final concentration 100 U each / mL penicillin / streptomycin (Gibco / BRL 15140-122), final concentration 100 ⁇ M ⁇ -mercaptoethanol (SIGMA M-7522), and final concentration 1000 U / mL ESGRO (LIF) (Gibco / BRL) What added 13275-029) was used (it is hereafter described as ES culture medium).
  • DMEM Dulbecco's modified Eagle's medium
  • MEF Mae Embryonic Fibroblast
  • the culture solution is DMEM (Gibco / BRL 11965-084), and the final concentration is 10%.
  • Fetal bovine serum Hyclone SH30071
  • final concentration 2 mM L-glutamine Gibco / BRL 25030-081
  • final concentration 100 ⁇ M each non-essential amino acid Gibco / BRL 11140-050
  • MEF medium Used each to which 100 U / mL penicillin / streptomycin (Gibco / BRL 15140-122) was added (hereinafter referred to as MEF medium).
  • MEF cells cultured to confluency in 150 cm 2 flasks are detached with trypsin / EDTA (0.05% / 1 mM, Gibco / BRL 25300-047), 4 10 cm dishes, 2 24-well plates, The solution was replated at optimal concentrations in two 6-well plates, six 25 cm 2 flasks, and two 75 cm 2 flasks.
  • Genotype analysis ES cells were prepared as follows. From the fifth day after gene transfer, emerging G418 resistant colonies were passaged to a 24-well plate as follows. Specifically, transfer G418 resistant colonies to a 96-well microplate containing 150 ⁇ L of trypsin / EDTA solution using Pipetman (Gillson), treat for 20 minutes in a 37 ° C incubator, and then pipet with Pipetman. It was a single cell. The cell suspension was transferred to a 24-well plate and culture was continued. Two days later, cells on a 24-well plate were split into two for cryopreservation and DNA extraction. That is, 500 ⁇ L of trypsin / EDTA was added to the cells, treated in an incubator at 37 ° C.
  • ES medium was added and gently pipetted into a single cell by pipetman. Thereafter, half of the cell suspension was transferred to a 24-well plate containing 1 mL of ES medium, and 1 mL of ES medium was also added to the original 24-well plate. After two more days, the medium of one 24-well plate was removed, and fetal bovine serum at a final concentration of 10% and dimethylsulfoxide (DMSO) at a final concentration of 10% were added to ES medium (Sigma D-5879) After 1 mL of freezing medium was added and sealed, it was stored frozen at -70 ° C.
  • DMSO dimethylsulfoxide
  • the assay of transgenic ES cells was performed by PCR as follows. That is, the medium was removed from each well of a 24-well plate in which cells were grown to confluence, washed with PBS and then 250 ⁇ L of lysis buffer (1% SDS, 20 mM EDTA, 20 mM Tris pH 7.5) and proteinase K 5 ⁇ L of (20 mg / mL) was added, shaken well, and dissolved by heating at 52 ° C. DNA was extracted from the dissolved sample by phenol / chloroform extraction and used as a template DNA for PCR.
  • lysis buffer 1% SDS, 20 mM EDTA, 20 mM Tris pH 7.5
  • proteinase K 5 ⁇ L (20 mg / mL
  • uPA transgenic ES cells were selected by the following procedure.
  • the PCR primers used were set in rabbit beta globin.
  • the sequence is the sense primer: GGGCGGGCGTACCGCATCTGAGAACTTCAGGGTGAG (SEQ ID NO: 1), antisense primer: GGGCGGCGGACTACAATTCTTTGCTAAATGATGAGA (SEQ ID NO: 2).
  • AmpliTaqGold (ABI). After activating the enzyme for 9 minutes at 95 ° C., the reaction was repeated 40 times at 94 ° C. for 30 seconds (denaturation), 63 ° C. for 30 seconds (annealing), and 72 ° C. for 1 minute (extension). After completion, the reaction solution was electrophoresed on a 2% agarose gel to confirm the PCR product.
  • Clones for which gene transfer was confirmed by PCR analysis were thawed by warming the cryopreserved 96-well plate to 37 ° C., and passaged to a 24-well plate. After culturing this 24-well plate at 37 ° C. for 24 hours, the medium was changed to remove DMSO and liquid paraffin. When each clone reached 75-90% confluence, it was passaged from 24 well to 6 well plate. Furthermore, when two wells were obtained which had grown to 75-90% confluency in a six-well plate, one well was cryopreserved, and the remaining one well was used for injection into blastocysts and DNA extraction. .
  • Cryopreservation was performed as follows. That is, cells are rinsed twice with PBS, 0.5 mL of Trypsin is added, incubated at 37 ° C. for 15 to 20 minutes, trypsinized, and then 0.5 mL of ES cell culture medium is added, and 35 to 40 times Petting was performed to completely dissociate the ES cell mass.
  • the cell suspension was transferred to a 15 mL centrifuge tube, and the wells were further washed with 1 mL of ES cell medium and collected in the tube. The tube was centrifuged at 1,000 rpm for 7 minutes, the medium was removed and resuspended in 0.25 mL ES cell medium and 0.25 mL of 2 ⁇ freezing medium was added. The contents of the wells were transferred to cryogenic vials, frozen at -80 ° C and stored in liquid nitrogen.
  • chimeric mice were prepared as follows. With respect to ES cell clones for which gene transfer was confirmed, chimeric embryos were prepared using blastocysts of C57BL / 6J strain mice as host embryos, and they were transplanted to the horns of pseudopregnant mice to obtain offspring. Harvesting of host embryos was performed on day 3 of gestation by perfusing the oviduct and uterus with Whitten's medium supplemented with 100 ⁇ M trypsin / EDTA. Eight-cell stage embryos or morula were cultured in Whitten's medium for 24 hours, and the obtained blastocysts were used for injection.
  • the ES cells used for injection were dispersed by TE treatment on the second or third day after passaging, and allowed to stand at 4 ° C. until being subjected to microscopic operation.
  • glass capillary tubing inner diameter about 20 ⁇ m
  • a micro glass tube NARISHIGE
  • P-97 / IVF microelectrode maker
  • De Fonburun a microforge
  • the injection pipette and the holding pipette were connected to a micromanipulator (Leica) to which a piezo system (Primetec PAMS-CT150) was connected.
  • a chamber used for micromanipulation a slide glass with a cover glass attached with beeswax is used, and two drops of Hepes-buffered Whitten's medium containing about 10 ⁇ L of 0.3% BSA are placed thereon.
  • the top was covered with mineral oil (Sigma).
  • One drop contains about 100 ES cells, the other contains about 20 expanded blastocysts, and about 15 ES cells are injected per embryo. All microscopic manipulations were performed under an inverted microscope.
  • Manipulated embryos were transferred to the uterine horn of an ICR-based recipient female on day 2 of pseudopregnancy.
  • the recipient females who did not take off their offspring even after the scheduled delivery date were subjected to cesarean section and were fostered by foster parents.
  • male chimeric mice were obtained in 39 clones.
  • mice (hemizygote, +/-) thus obtained are backcrossed twice to SCID-bg mice, and mice having the uPA-Tg (+/-) SCID (+ / +) genotype are selected. Obtained.sperm were collected from males of the mice and returned to the post-mortem after unfertilized eggs and in vitro fertilization of SCID mice (homozygote, + / +). Among the born offspring mice, mice containing a Tg gene were selected, and by natural mating, mice uPA-Tg (+/-) / SCID (+ / +) having both traits were obtained.
  • uPA-Tg (+/-) and uPA-Tg (-/-) were carried out by genomic PCR using a sequence specific for the transgene as a primer.
  • SCID (+ / +), SCID (+/ ⁇ ) and SCID ( ⁇ / ⁇ ) was performed by the PCR-RFLP method.
  • uPA-Tg (+/-) / SCID (+ / +) are crossed, and uPA-Tg (+ / +) / SCID (+ / +) and uPA-Tg (+/-) / SCID (+ / +) was obtained.
  • the discrimination between uPA-Tg (+ / +) and uPA-Tg (+/-) was performed by Southern blotting. The tails of 8-10 day-old mice were cut about 5 mm, solubilized with SDS, proteinase K solution, and phenol and chloroform extraction were performed to remove contaminating protein components.
  • genomic DNA was precipitated by isopropanol precipitation.
  • the above genomic DNA was washed with 70% ethanol, allowed to air dry, and then redissolved in TE.
  • the genomic DNA extracted from the sample, the genomic DNA of positive and negative controls, and 5 ⁇ g each were completely digested with EcoR1, and the resulting DNA fragments were separated by agarose electrophoresis and transferred to a nylon membrane.
  • a DNA fragment suitable for Southern hybridization probe was purified from uPA cDNA probe / TA using restriction enzyme EcoR1 (379 bp). The above DNA fragment was [32P] labeled by the random prime method.
  • the DNA fragment transferred to the nylon membrane was hybridized with the RI labeled uPA cDNA probe.
  • the nonspecifically bound probe was removed by washing, and the radioactive signal derived from the foreign gene introduced into the candidate individual of the mAlb-uPA-Int2 Tg mouse was detected by exposure to X-ray film.
  • Genotype of mAlb-uPA-Int2 Tg mouse individual by detecting specific signal of 1.5 kb from wild type locus and specific signal of 0.4 kb (wt: 1.5 kb) from mutant type locus was judged.
  • uPA-Tg (+ / +) / SCID (+ / +) mice and SCID / cb-17 mice are multiplied to obtain uPA-Tg (+/-) / SCID (+ / +) mice
  • the uPA-Tg (+ / +) / SCID (+ / +) mice were used for primary transplantation, and uPA-Tg (+/-) / SCID (+ / +) mice were used as host mice for passage.
  • hepatocytes purchased from BD Gentest (Lot No. BD 195, girl, 2 years old) and hepatocytes purchased from BioIVT (Lot No. IVTJFC, boy, 1 year old) I used each.
  • mice Three to five week-old uPA-Tg (+ / +) / SCID (+ / +) mice are anesthetized with isoflurane, and an incision of about 5 mm in the left flank is made and 10.0 ⁇ 10 5 human hepatocytes are obtained from the splenic head. After injection, the spleen was returned to the abdominal cavity and sutured. After transplantation, the animals were reared for about 100 days by free intake of tap water supplemented with common feed CRF-1 (Oriental Yeast Co., Ltd.) and sodium hypochlorite solution 0.0125%.
  • CRF-1 Oriental Yeast Co., Ltd.
  • SCID / c.b-17 mice used for cross-linking do not have T cells or B cells but have NK cells. Therefore, an antibody that inhibits NK activity was intraperitoneally administered the day before transplantation so that the transplanted human hepatocytes were not attacked by mouse NK cells.
  • the percent replacement of human hepatocytes in the livers of the resulting primary chimeric mice was 90-95%.
  • This substitution rate was determined by measuring human albumin concentration in mouse blood. That is, blood is collected from the tail vein of a chimeric mouse, and 2 ⁇ l of collected blood is added to 200 ⁇ L of LX-Buffer, and human albumin in the blood of mouse is obtained by using an automatic analyzer JEOL BM 6050 (Nippon Denshi) by immunoturbidimetry. The concentration was measured. The human albumin concentration was applied to a calibration curve prepared in advance to estimate the human hepatocyte replacement rate.
  • the standard curve is used to prepare a frozen section of the chimera mouse liver and to perform immunostaining using human hepatocyte-specific cytokeratin 8/18 antibody (ICN Pharmaceuticals, Inc.). An 18 positive area was determined between human hepatocyte substitution rate and human albumin concentration in chimera mouse blood.
  • the passage-transplanted human hepatocyte chimera mouse obtained in the item of “(2) Generation of passage-transplanted human hepatocyte chimera mouse” was treated with a superhigh fat choline deficient methionine reduction diet (A06071302; Research Diets, Inc) or a normal diet.
  • a certain amount of CRF-1 (Oriental Yeast Co., Ltd.) and sodium hypochlorite solution 0.0125% added were fed for 12 or 14 weeks by free intake of tap water.
  • 4 rats were fed with a superhigh fat choline-deficient methionine reduction diet, and 3 rats were fed a normal feed feeding group.
  • the superhigh fat choline deficient methionine reduced feed group was 3 and the normal feed group was 3 or 4.
  • Blood was collected from the tail vein of passaged chimeric mice bred with adjusted diet and regular diet, respectively, before starting the test, 2 weeks, 4 weeks, 8 weeks and 12 weeks, and 2 ⁇ l of collected blood was physiological was added to brine 200 [mu] L, latex agglutination turbidimetric immunoassay (LZ test 'Eiken' U-ALB, Eiken Chemical Co., Ltd., Tokyo) using an automatic analyzer BioMajesty TM (JCA-BM6050, JEOL , Tokyo Blood albumin concentration (mg / ml) was measured.
  • the super-high fat choline deficient methionine reduced diet (A06071302; Research Diets, Inc) does not contain choline or its salt, but adds L-methionine to a final concentration of 0.1% by weight. Also, the ratio of the heat of fat to the total heat of protein, carbohydrate and fat is 62 kcal%. Also, the fat content is 35.7% by weight based on the total weight of the feed.
  • the time course of the ALT activity of passage-transplanted chimeric mice transplanted with human hepatocyte Lot No. BD195 is shown in FIG.
  • mouse ALT activity was not increased, but human ALT activity was found to increase after 2 weeks and 4 weeks, and to be in parallel with total ALT activity. It can be seen that liver damage was induced specifically to human hepatocytes by feeding on the adjusted diet.
  • passage-transplanted human hepatocyte chimera mouse obtained in the item of "(2) passage-transplanted human hepatocyte chimera mouse" is a choline-deficient methionine reduced high-fat diet (CDAHFD) (super-high fat fat) Choline deficient methionine weight loss diet ⁇ A06071302) (Research Diets, Inc) or CRF-1 (Oriental Yeast Co., Ltd.) which is a regular diet, and free intake of tap water supplemented with 0.0125% sodium hypochlorite solution were raised for 12 weeks.
  • CDAHFD choline-deficient methionine reduced high-fat diet
  • CRF-1 Oriental Yeast Co., Ltd.
  • FIG. 1 a histology at a magnification of 400 times after 12 weeks for passage-transplanted chimeric mice into which human hepatocyte Lot No. BD195 has been transplanted is shown in FIG.
  • FIG. 1 a histology at 400 times magnification after 14 weeks for passage-transplanted chimeric mice into which human hepatocyte Lot No. IVTJFC has been transplanted is shown in FIG.
  • inflammatory cell infiltration such as macrophages is observed unlike in the case of rearing on regular diet, and Ballooning cells (balloon-like tumors of hepatocytes have a structure like Mallory bodies in the cytoplasm Large) (arrowhead) was observed. It can be seen that chronic administration of the adjusted diet induced lesions characteristic of human NASH.
  • paraffin sections of liver 12 weeks after the start of the test for passage-transplanted chimeric mice into which human hepatocyte Lot No. BD195 had been transplanted were prepared and subjected to Sirius red staining. Histograms at 40 ⁇ and 400 ⁇ magnification are shown in FIG.
  • paraffin sections of the liver 14 weeks after the start of the test were prepared and stained with Sirius red. A 400 ⁇ histology is shown in FIG.
  • the area of fibrosis (the part stained with red) is larger than in the case of rearing on regular feed, and pericellular or perisinusoidal fibrosis that extends around the central vein or portal vein area is It was observed. Sirius red positive area (fibrotic area) per total area on Sirius red stained tissue sections for passaged transplanted chimeric mice transplanted with human hepatocyte Lot No. BD195 was calculated. The results are shown in FIG. By feeding on the adjusted diet, it can be seen that the fibrotic portion increases about 1.6 times after 8 weeks and increases about 2.4 times after 12 weeks as compared to feeding on the regular feed .
  • F4 / 80 is one of the antigens expressed in Kupffer cells in the liver, macrophages and the like, and Kupffer cells and macrophages can be stained in brown by immunostaining using an anti-F4 / 80 antibody.
  • the immunostaining image of the anti-F4 / 80 antibody is shown in FIG. In the case of rearing on adjusted diet, it is clear that the portion stained in brown is clearly more than that on rearing on regular feed, and that Kupffer cells and macrophages are increased.
  • ⁇ SMA is a marker of activated hepatic stellate cells, and activated hepatic stellate cells produce collagen fibers and are considered to play an important role in fibrosis of the liver. Activated stellate cells can be stained brown by immunostaining with an ⁇ SMA antibody.
  • the immunostaining image (magnification of 100 times) of the ⁇ SMA antibody is shown in FIG. It can be seen from FIG. 11 that in any of the periods reared with the adjusted feed, the ⁇ SMA positive region staining brown is clearly increased as compared with the rearing with the normal feed.
  • a TUNEL stained image (magnification of 100 times) of a passage-transplanted chimeric mouse into which human hepatocyte Lot No. BD195 has been transplanted is shown in FIG.
  • paraffin sections of liver 8 weeks and 12 weeks after the start of the test were stained by TUNEL method.
  • the TUNEL method is a staining method that specifically stains cells that have undergone apoptosis. It can be seen from FIG. 12 that, when reared with the adjusted feed, the TUNEL-positive cells stained brown are clearly increased as compared with the rearing with the normal feed. Since apoptosis is an aspect of cell death that is characteristic of NASH, it can be seen that NASH symptoms were induced by feeding on a controlled diet.
  • the paraffin section of the liver 12 weeks after a test start was produced, and the Sirius red stain was performed.
  • a histology at 400 ⁇ is shown in FIG.
  • the area of fibrosis (the part stained with red) is larger than in the case of rearing on regular feed, and pericellular or perisinusoidal fibrosis that extends around the central vein or portal vein area is It was observed.
  • paraffin sections of the liver 12 weeks after the start of the test for primary human hepatocyte chimeric mice transplanted with human hepatocyte Lot No. IV TJFC were immunostained using anti-F4 / 80 antibody (clone BM8, BMA Biomedicals)
  • the immunostaining image of the anti-F4 / 80 antibody is shown in FIG.
  • the portion stained in brown is clearly more than that on rearing on regular feed, and that Kupffer cells and macrophages are increased.
  • CCl 4 Carbon tetrachloride
  • ALT activity in the plasma was determined by Fuji Dry Chem 7000 (Fuji Film) and Fuji Dry Chem Slide GTP / ALT-PIII (Fuji Film) And human ALT1 concentration (ng / mL) was measured using an ELISA kit (human ALT1 ELISA kit, Phoenix Bio Inc.). Furthermore, human ALT activity (U / L) was determined from human ALT1 concentration (ng / mL).
  • euthanasia was performed 7 days after CCl 4 administration of human hepatocyte chimeric mice, and euthanasia was performed in SCID mice because of poor prognosis 2 days after CCl 4 administration.
  • Paraffin sections of liver were prepared and subjected to HE staining. A histology at 40 ⁇ magnification is shown in FIG.
  • necrosis of hepatocytes was observed specifically in the mouse region (arrow), and in liver tissue of SCID mice, extensive necrosis of hepatocytes was observed (arrow). This also indicates that CCl 4 administration is difficult to cause specific damage to human hepatocytes.
  • Control animals of the model of the present invention As shown on the left of FIG. 3 and FIG. 4, passaged transplant chimera mice reared on a normal diet show pathological condition of simple fatty liver. Also, as shown in this test, passaged chimeric mice do not progress from simple fatty liver to NASH, even when fed with normal diet for a long time. Therefore, passaged chimeric chimeras can be used as a model of human simple fatty liver and can be used as a control animal of the NASH model of the present invention.
  • the human non-alcoholic steatohepatitis rodent animal model of the present invention accurately reflects human NASH because the liver is replaced with human hepatocytes. Since the NASH symptoms can be obtained stably, it can be suitably used as a model of rodent animals having human hepatocytes for research on the pathogenesis of NASH, screening of agents for preventing, treating or ameliorating NASH, and the like.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un modèle de stéatohépatite non alcoolique humaine qui comprend un animal obtenu par alimentation d'un rongeur chimérique, dans lequel les hépatocytes ont été partiellement ou totalement substitués par des hépatocytes humains, avec une alimentation ajustée ayant une ou plusieurs caractéristiques sélectionnées parmi : (a) la teneur en choline ou un sel de celle-ci étant de 0,01 % en poids ou moins par rapport à la quantité totale de l'alimentation ajustée ; (b) la teneur en méthionine étant inférieure ou égale à 0,5 % en poids par rapport à la quantité totale de l'alimentation ajustée ; et (c) la teneur en graisse étant de 25 % en kcal ou plus par rapport à la valeur calorique totale des protéines, des glucides et des graisses contenus dans l'alimentation ajustée. Ce modèle présente de manière stable les symptômes de la stéatohépatite non alcoolique humaine.
PCT/JP2018/040601 2017-11-01 2018-10-31 Modèle de stéatohépatite non alcoolique humaine WO2019088208A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019550478A JP7233039B2 (ja) 2017-11-01 2018-10-31 ヒト非アルコール性脂肪性肝炎モデル

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017211919 2017-11-01
JP2017-211919 2017-11-01

Publications (1)

Publication Number Publication Date
WO2019088208A1 true WO2019088208A1 (fr) 2019-05-09

Family

ID=66331918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/040601 WO2019088208A1 (fr) 2017-11-01 2018-10-31 Modèle de stéatohépatite non alcoolique humaine

Country Status (2)

Country Link
JP (1) JP7233039B2 (fr)
WO (1) WO2019088208A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226070A1 (fr) * 2019-05-08 2020-11-12 株式会社フェニックスバイオ Modèle humain de stéatohépatite non alcoolique
CN112714789A (zh) * 2019-08-26 2021-04-27 飞氏生物株式会社 人脂肪肝模型细胞
WO2021132117A1 (fr) * 2019-12-23 2021-07-01 積水メディカル株式会社 Procédé de mesure du taux de remplacement des hépatocytes humains dans un animal chimérique comprenant des hépatocytes humains
KR20220138600A (ko) * 2021-04-06 2022-10-13 (주)메디픽 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349457A (ja) * 2005-06-15 2006-12-28 Tokyo Medical & Dental Univ 非アルコール性脂肪肝の治療薬のスクリーニング方法
WO2008001614A1 (fr) * 2006-06-29 2008-01-03 Hiroshima Industrial Promotion Organization Modèle animalier de stéatohépatite non alcoolique et modèle animalier de stéatose hépatique
JP2012080830A (ja) * 2010-10-12 2012-04-26 Mitsubishi Chemical Medience Corp ヒト非アルコール性脂肪性肝炎（ｎａｓｈ）の非ヒトモデル動物
WO2013015331A1 (fr) * 2011-07-25 2013-01-31 株式会社ヤクルト本社 Animal modèle de stéato-hépatite non alcoolique (nash)
WO2015170694A1 (fr) * 2014-05-08 2015-11-12 株式会社フェニックスバイオ Modèle d'hyperuricémie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349457A (ja) * 2005-06-15 2006-12-28 Tokyo Medical & Dental Univ 非アルコール性脂肪肝の治療薬のスクリーニング方法
WO2008001614A1 (fr) * 2006-06-29 2008-01-03 Hiroshima Industrial Promotion Organization Modèle animalier de stéatohépatite non alcoolique et modèle animalier de stéatose hépatique
JP2012080830A (ja) * 2010-10-12 2012-04-26 Mitsubishi Chemical Medience Corp ヒト非アルコール性脂肪性肝炎（ｎａｓｈ）の非ヒトモデル動物
WO2013015331A1 (fr) * 2011-07-25 2013-01-31 株式会社ヤクルト本社 Animal modèle de stéato-hépatite non alcoolique (nash)
WO2015170694A1 (fr) * 2014-05-08 2015-11-12 株式会社フェニックスバイオ Modèle d'hyperuricémie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MINICS, SAMUELE DE ET AL.: "Role and Cellular Source of Nicotinamide Adenine Dinucleotide Phosphate Oxidase in Hepatic Fibrosis", HEPATOLOGY, vol. 52, 2010, pages 1420 - 1430, XP55612265 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226070A1 (fr) * 2019-05-08 2020-11-12 株式会社フェニックスバイオ Modèle humain de stéatohépatite non alcoolique
CN112714789A (zh) * 2019-08-26 2021-04-27 飞氏生物株式会社 人脂肪肝模型细胞
EP4039797A4 (fr) * 2019-08-26 2023-08-30 PhoenixBio Co., Ltd. Cellules de modèle de foie gras humain
WO2021132117A1 (fr) * 2019-12-23 2021-07-01 積水メディカル株式会社 Procédé de mesure du taux de remplacement des hépatocytes humains dans un animal chimérique comprenant des hépatocytes humains
JPWO2021132117A1 (fr) * 2019-12-23 2021-07-01
JP7037789B2 (ja) 2019-12-23 2022-03-17 積水メディカル株式会社 ヒト肝細胞キメラ動物におけるヒト肝細胞置換率の測定方法
KR20220138600A (ko) * 2021-04-06 2022-10-13 (주)메디픽 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도
KR102679687B1 (ko) 2021-04-06 2024-06-28 곽민진 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도

Also Published As

Publication number Publication date
JP7233039B2 (ja) 2023-03-06
JPWO2019088208A1 (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
WO2019088208A1 (fr) Modèle de stéatohépatite non alcoolique humaine
JP5172670B2 (ja) 非アルコール性脂肪性肝炎モデル動物及び脂肪肝モデル動物
CN106987604B (zh) 一种制备动脉粥样硬化疾病模型犬的方法
JP5841322B2 (ja) フマリルアセト酢酸ヒドロラーゼ（ｆａｈ）欠損性ブタおよびその使用
Haueter et al. Genetic vasectomy—Overexpression of Prm1‐EGFP fusion protein in elongating spermatids causes dominant male sterility in mice
WO2010082385A1 (fr) Souris possédant des hépatocytes humains transplantés
EP2024503A2 (fr) Modèle animal et méthode d'obtention d'un tel modèle
US11051496B2 (en) Urokinase-type plasminogen activator transgenic mouse
JP6496107B2 (ja) 高尿酸血症モデル
JPWO2008001778A1 (ja) 遺伝子改変動物およびその用途
JP2023116719A (ja) 安定した表現型を示す疾患モデルブタおよびその作製方法
JP7037789B2 (ja) ヒト肝細胞キメラ動物におけるヒト肝細胞置換率の測定方法
WO2020226070A1 (fr) Modèle humain de stéatohépatite non alcoolique
US11882816B2 (en) Genetically engineered non-human mammal, construction method therefor and use thereof
US20040073958A1 (en) Transgenic animal having drug metabolism enzyme gene and utilization thereof
JP5979629B2 (ja) 神経変性疾患モデル非ヒト哺乳動物
JP5692677B2 (ja) 非ヒトノックアウト動物、並びにその用途およびその作製方法
CN107974465B (zh) Slc6a13基因及其蛋白的用途
JPH08511688A (ja) Ｅｃ−ｓｏｄの形質転換生産
JP4940477B2 (ja) Ｏａｓｉｓ遺伝子欠損マウス
US20090320147A1 (en) Nonhuman transgenic animal as type 2 diabetes model
WO2004092371A1 (fr) Souris presentant une deficience de la fonction glast de transporteur de glutamate
KR20030035121A (ko) Ｓｒｇ３ 유전자 결핍 생쥐 및 그의 제조방법
WO1997003555A1 (fr) Modele animal transgenique d'osteopenie
JP2006141283A (ja) ３−ホスホグリセレートデヒドロゲナーゼの発現が低下したノックアウト非ヒト哺乳動物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18872513

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019550478

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18872513

Country of ref document: EP

Kind code of ref document: A1